GLP-3-RT

GLP-3-RT is a synthetic peptide designed for research applications in the study of glucagon-like peptide-3 receptor (GLP-3R) signaling pathways. This compound is intended for use by qualified investigators engaged in basic or translational research related to gastrointestinal physiology, endocrine function, and metabolic regulation. GLP-3-RT is not intended for therapeutic, diagnostic, or cosmetic purposes and must be handled with strict adherence to laboratory safety protocols.

Research Context

The glucagon-like peptide-3 receptor (GLP-3R) plays a critical role in regulating gastrointestinal motility, hormone secretion, and satiety responses. GLP-3R signaling is implicated in conditions affecting gut function, such as motility disorders, inflammatory bowel disease (IBD), and metabolic disorders, including diabetes and obesity. Research involving GLP-3R agonists or antagonists has the potential to advance understanding of these pathways, although direct clinical applications remain speculative at this stage.

Research Overview

GLP-3-RT is synthesized to evaluate its binding affinity, functional activity, and specificity toward GLP-3R in vitro and in vivo models. This peptide is primarily utilized in cellular assays, recombinant expression systems, and preclinical animal studies to assess receptor-mediated effects on gut hormone release, enteric nervous system activity, and metabolic responses. Due to its potential interaction with GLP-3R, careful consideration must be given to off-target effects, particularly in systems where related receptors (e.g., GLP-1R) may exhibit cross-reactivity.

Key Research Focus Areas

• GLP-3R Binding and Functional Assays:
  – Evaluation of peptide-receptor binding kinetics via surface plasmon resonance (SPR), ELISA, or receptor-binding assays.
• In Vitro Pharmacology:
  – Assessment of GLP-3R-mediated signaling in transfected cell lines (e.g., HEK293, CHO) or primary enteric neurons.
• In Vivo Models:
  – Administration in rodents (e.g., mice, rats) to study gastrointestinal motility, hormone release (e.g., GLP-3, GLP-1), and metabolic outcomes.
• Cross-Reactivity Studies:
  – Comparison with endogenous GLP-3 or GLP-1 peptides to determine specificity and avoid confounding effects.
• Toxicology and Safety Profiles:
  – Evaluation of acute and chronic toxicity, systemic distribution, and potential off-target effects in research settings.

Safety Considerations

GLP-3-RT must be handled with the same caution as any research peptide or small molecule. Potential risks include unintended receptor activation, immunogenicity, or pharmacokinetic interactions with endogenous signaling pathways. Investigators should follow institutional biosafety protocols, including proper storage (e.g., refrigerated or lyophilized), disposal procedures, and documentation of usage. Inhalation, ingestion, or accidental exposure to GLP-3-RT is highly prohibited.

For research use only. Not for human or animal consumption.